전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved90 programs
CGTCurated CoreFDAVertexApproved

exagamglogene autotemcel (Casgevy, exa-cel, CTX001)

Sickle cell disease with recurrent VOCs; transfusion-dependent β-thalassemia · BCL11A enhancer (CRISPR/Cas9) → HbF

#BCL11AenhancerCRISPRCas9HbF#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 9Status Approved
CGTCurated CoreFDAbluebird bioApproved

lovotibeglogene autotemcel (Lyfgenia, lovo-cel, bb1111)

Sickle cell disease with recurrent vaso-occlusive events · βA-T87Q-globin (lentiviral)

#A-T87Q-globinlentiviral#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 2Status Approved
CGTLimited DatastaleThomas Martin, MDPhase 1

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

Multiple Myeloma; Recurrent Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 211Status Discontinued
CGTStandard DatabasestaleMerck Sharp & Dohme LLCPhase 3

Recombinant Interferon Alfa-2b (Recombinant Interferon Alfa-2b)

Recurrent Melanoma; Stage IIIA Cutaneous Melanoma AJCC v7 · HER2

#HER2#CGT#Phase3#Popular#cell-gene-therapy+5
Trials 83Status Recruiting
CGTLimited DatastaleIstituto Clinico HumanitasPreclinical

immune evaluation (immune evaluation)

Oligorecurrent and Oligoprogressive Prostate Cancer Patients · Oligorecurrent and Oligoprogressive Pros

#OligorecurrentandOligoprogressiv#CGT#Preclinical#Popular#cell-gene-therapy+4
Trials 61Status Recruiting
CGTLimited DatastaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting
CGTLimited DatastaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting
CGTLimited DatastaleLion TCR Pte. Ltd.Phase 1

Biological: TCR-T (Biological: TCR-T)

Recurrent Hepatocellular Carcinoma · Recurrent Hepatocellular Carcinoma

#RecurrentHepatocellularCarcinoma#CGT#Phase1#Popular#cell-gene-therapy+4
Trials 58Status Active
CGTLimited DatastaleRoyan InstitutePhase 1

NK cell therapy (NK cell therapy)

Glioblastoma Multiform; Recurrent Glioblastoma · Glioma Glioblastoma Multiforme

#GliomaGlioblastomaMultiforme#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 58Status Active
CGTStandard DatabasestaleGeneplus-Beijing Co. Ltd.Phase 2

natural killer cell infusion (natural killer cell infusion)

Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood B-Lymphoblastic Lymphoma · Recurrent B-Cell Childhood Acute Lymphob

#RecurrentB-CellChildhoodAcuteLym#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 58Status Active
ADCStandard DatabasestaleRocheDM1 via butelase-1 with ABD…Phase 2

ado-trastuzumab emtansine (Kadcyla, T-DM1)

HER2 Positive Breast Carcinoma; Recurrent Breast Carcinoma · HER2

#HER2#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 57Status Active
CGTLimited DatastaleMarzieh EbrahimiPhase 1

Allogenic NK cells infusion (Allogenic NK cells infusion)

Neuroblastoma, Recurrent, Refractory; Neuroblastoma (NB) · FRα

#FR#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 56Status Recruiting
CGTLimited DatastaleInternational Brain Research Fo…Phase 2

Quercetin (Quercetin)

Recurrent Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 54Status Recruiting
ADCStandard DatabasestalePfizerPhase 3

Inotuzumab ozogamicin (Inotuzumab ozogamicin)

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#ADC#Phase3#Popular#antibody-drug-conjugate+5
Trials 53Status Recruiting
CGTLimited DatastaleSecuraBioPhase 1

Duvelisib (Duvelisib)

Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 45Status Active
CGTLimited DatastaleRui Therapeutics Co., LtdPhase 1

anti-CD19 CAR-NK cells (anti-CD19 CAR-NK cells)

Refractory/Recurrent Central Nervous System Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 32Status Active
CGTStandard DatabasestaleQingdao Haier Biotechnology Co.…Phase 2

autologous NK cell (autologous NK cell)

NK Cell; B-cell Lymphoma Recurrent · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 31Status Recruiting
AntibodyLimited DatastaleADC TherapeuticsPhase 3

Loncastuximab tesirine (Loncastuximab tesirine)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3b Follicular Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#monoclonal-antibody#RecurrentDiffuseLargeB-CellLymph+2
Trials 30Status Recruiting
AntibodyLimited DatastaleJohn ReneauPhase 1

Mogamulizumab (Mogamulizumab)

Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Cutaneous T Cell Lymphoma

#CutaneousTCellLymphoma#Antibody#Phase1#monoclonal-antibody#RecurrentAdultT-CellLeukemia+3
Trials 30Status Recruiting
ADCCurated CorestaleMerck Sharp & Dohme LLCPhase 3

Ifinatamab deruxtecan (Ifinatamab deruxtecan)

Recurrent or Metastatic Solid Tumors · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#BioJungboMoa-pick#antibody-drug-conjugate+2
Trials 18Status Recruiting

1 / 5 pages

← PreviousNext →